MARKET

LTGO

LTGO

Latigo Biotherapeutics, Inc.
NASDAQ
14.04
-0.53
-3.64%
After Hours: 14.00 -0.04 -0.28% 18:28 11/04 EST
OPEN
14.87
PREV CLOSE
14.57
HIGH
15.16
LOW
13.96
VOLUME
155.96K
TURNOVER
--
52 WEEK HIGH
25.93
52 WEEK LOW
13.26
MARKET CAP
930.84M
P/E (TTM)
-18.2101
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LTGO last week (1026-1030)?
Weekly Report · 2d ago
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha · 6d ago
'Trump Administration Backs Down on an Opioid Ban After Kratom Industry Lobbying' - NY Times
Benzinga · 10/28 11:29
Weekly Report: what happened at LTGO last week (1019-1023)?
Weekly Report · 10/26 10:34
Weekly Report: what happened at LTGO last week (1012-1016)?
Weekly Report · 10/19 10:34
Weekly Report: what happened at LTGO last week (1005-1009)?
Weekly Report · 10/12 10:41
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It
Seeking Alpha · 10/11 20:31
Weekly Report: what happened at LTGO last week (0928-1002)?
Weekly Report · 10/05 10:40
More
About LTGO
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its two product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors designed to inhibit the transmission of pain. It is also advancing additional Nav1.8 candidates that can address alternative formulation and delivery approaches. The Company's lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-321 is its next-generation candidate for the inhibition of Nav1.8, being developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis (OA). LTG-001 and LTG-321 are in clinical development, and LTG-418 and the Company's other product candidates and programs are in preclinical development or discovery stages.

Webull offers Latigo Biotherapeutics, Inc. stock information, including NASDAQ: LTGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTGO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTGO stock methods without spending real money on the virtual paper trading platform.